The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G
Open accessAbstract
Activated and in vitro expanded natural killer (NK) cells have substantial cytotoxicity against many tumor cells, but their in vivo efficacy to eliminate solid cancers is limited. Here, we used chimeric antigen receptors (CARs) to enhance the activity of NK cells against Ewing sarcomas (EwS) in a tumor antigen-specific manner. Expression of CARs directed against the ganglioside antigen GD2 in activated NK cells increased their responses to GD2+ allogeneic EwS cells in vitro and overcame resistance of individual cell lines to NK cell lysis. Second-generation CARs with 4-1BB and 2B4 co-stimulatory signaling and third-generation CARs combining both co-stimulatory domains were all equally effective. By contrast, adoptive transfer of GD2-specific CAR gene-modified NK cells both by intratumoral and intraperitoneal delivery failed to eliminate GD2-expressing EwS xenografts. Histopathology review revealed upregulation of the immunosuppressive ligand HLA-G in tumor autopsies from mice treated with NK cells compared to untreated control mice. Supporting the relevance of this finding, in vitro co-incubation of NK cells with allogeneic EwS cells induced upregulation of the HLA-G receptor CD85j, and HLA-G1 expressed by EwS cells suppressed the activity of NK cells from three of five allogeneic donors against the tumor cells in vitro.We conclude that HLA-G is a candidate immune checkpoint in EwS where it can contribute to resistance to NK cell therapy. HLA-G deserves evaluation as a potential target for more effective immunotherapeutic combination regimens in this and other cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GD2-specific CAR-NK cells for Ewing sarcoma failed to eliminate GD2-positive sarcoma in xenografts models [71].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [71]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Adoptive NK cells showed initial success in the treatment of osteosarcoma [71].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [71]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“Adoptive therapy with T cells gene-modified to express CARs against the B cell antigen CD19 was highly active to induce remissions in patients with B cell malignancies.(15,16) EwS is a candidate tumor for CAR targeting by surface expression of the ganglioside antigen GD2.”
BackgroundLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195 · cited 1×
“An example could be CAR T cell targeting of solid tumors that so far has been less successful than of lymphoid malignancies.(44,45) To ultimately clarify the relevance of HLA-G in adoptive cell therapy of EwS, experiments with downregulated HLA-G by antibody blockade or gene editing are needed.”
BackgroundCarpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888 · cited 1×
“In T cells, combined signals from two co-stimulatory molecules have further augmented CAR-mediated T cell activation in some models.(23,24) Such third-generation CARs have not yet been evaluated in NK cells.”
BackgroundRajagopalan, S., & Long, E. O. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1093 · Cited by 726
Rouas-Freiss, N., Gonçalves, R. M.-B., Menier, C., Dausset, J., & Carosella, E. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11520 · Cited by 701
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694 · cited 2×
“PD-1 pathway inhibition was a key obstacle to CAR T cell therapy of solid tumors in preclinical models.(26,27) NK cells can also induce PD-L1 upregulation on tumor cells, and this results in a substantial reduction of their capacity to lyse tumor cells.”
BackgroundResultCytokine activation induces human memory-like NK cells
Romee, R., Schneider, S. E., Leong, J. W., Chase, J. M., Keppel, C. R., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2012) · Blood · doi:10.1182/blood-2012-04-419283 · Cited by 684 · cited 2×
“These cytokines were reported to promote high proliferation rates and an increased proportion of NK cells with enhanced functional capacity.(20) IL-15 signals are provided to both types of cultures by membrane-bound IL-15 on the stimulator cells.”
BackgroundMethodImai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659 · cited 8×
“Expression of second- and third-generation CARs in activated human NK cells can enhance their in vitro antitumor activity in an antigen-dependent manner To overcome resistance of EwS cells to targeting by activated NK cells, we engineered allogeneic NK cells to express CARs directed against the surface ganglioside GD2…”
BackgroundMethodInfluentialHanenberg, H., Xiao, X. L., Dilloo, D., Hashino, K., Kato, I., & Williams, D. A. (1996) · Nature Medicine · doi:10.1038/nm0896-876 · Cited by 542
Self-citation
Research works printed but not linked: 1
- Ibrahim EC, 2001, Cancer Res, 61, 6838
Cited by
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R., Liu, E., & Shpall, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 453
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“GD2-specific CAR-NK cells for Ewing sarcoma failed to eliminate GD2-positive sarcoma in xenografts models [71].”
BackgroundDevelopment of NK cell-based cancer immunotherapies through receptor engineering
Page, A., Chuvin, N., Valladeau-Guilemond, J., & Depil, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01145-x · Cited by 219
“For instance, some CARs have been designed with intracellular regions based on the activating receptors 2B4 [44, 60, 62, 64 – 66] and NKG2D [61], the adapter proteins DAP10 [57] and DAP12 [59, 67, 68], or the Fc receptors Fc ε R γ [69] and CD16 [63].”
BackgroundCAR-NK for tumor immunotherapy: Clinical transformation and future prospects
Wang, W., Jiang, J., & Wu, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.033 · Cited by 221
Daher, M., & Rezvani, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0556 · Cited by 219
Metadata
- Authors
- Kailayangiri, S., Altvater, B., Spurny, C., Jamitzky, S., Schelhaas, S., Jacobs, A. H., Wiek, C., Roellecke, K., Hanenberg, H., Hartmann, W., Wiendl, H., Pankratz, S., Meltzer, J., Farwick, N., Greune, L., Fluegge, M., & Rossig, C.
- Affiliations
- University of Münster (DE)
- Heinrich Heine University Düsseldorf (DE)
- University Hospital Münster (DE)
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2016-10-28
- Volume
- 6
- Issue
- 1
- Pages
- e1250050
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5283645
- OpenAlex
- W2546024518
- Cited by
- 104
- References
- 50
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 15 · 2021: 25 · 2020: 15 · 2019: 8 · 2018: 5 · 2017: 7
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Krebshilfe
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- Ewing sarcoma, GD2, chimeric antigen receptor, natural killer cells, HLA-G, immune checkpoint, 4-1BB, adoptive immunotherapy, tumor resistance, NK cell therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. https://app.cochat.ai/papers/10.1080/2162402x.2016.1250050
- The paper
- Kailayangiri, S., Altvater, B., Spurny, C., Jamitzky, S., Schelhaas, S., Jacobs, A. H., Wiek, C., Roellecke, K., Hanenberg, H., Hartmann, W., Wiendl, H., Pankratz, S., Meltzer, J., Farwick, N., Greune, L., Fluegge, M., & Rossig, C. (2017). Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1250050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.